<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Donepezil and memantine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Donepezil and memantine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Donepezil and memantine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="99503" href="/d/html/99503.html" rel="external">see "Donepezil and memantine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F27773342"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Namzaric</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26715480"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acetylcholinesterase Inhibitor (Central);</li>
<li>
                        N-Methyl-D-Aspartate (NMDA) Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F27657696"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3041b3d-3f11-47c1-815e-01b475c1f691">Alzheimer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease (moderate to severe):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Patients stabilized on donepezil 10 mg once daily and not currently on memantine: Initial: Memantine extended release (ER) 7 mg/donepezil 10 mg once daily in the evening. Increase dose in increments of memantine ER 7 mg at intervals of ≥1 week to maintenance dose of memantine ER 28 mg/donepezil 10 mg once daily based on patient response and tolerability. Maximum dose: memantine ER 28 mg/ donepezil 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients stabilized on memantine (10 mg twice daily or 28 mg ER once daily) and donepezil 10 mg: Initial: Memantine ER 28 mg/donepezil 10 mg once daily in the evening. Initiate combination therapy the day after the last dose of memantine and donepezil administered separately.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Discontinuation of therapy may result in worsening of cognitive function (Howard 2012). Avoid abrupt discontinuation except in the case of severe adverse drug reaction to minimize withdrawal symptoms (eg, altered mental status, hallucinations, delusions, insomnia, increased anxiety and agitation). In general, cholinesterase inhibitors and memantine should be tapered using a 50% dose reduction or stepwise reduction via available dose formulations every 4 weeks to the lowest dose prior to discontinuation. Consider re-initiation if clear worsening of the condition occurs after withdrawal (Reeve 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991539"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (CrCl 30 to 80 mL/minute): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe renal impairment (CrCl 5 to 29 mL/minute):</p>
<p style="text-indent:-2em;margin-left:4em;">Patients stabilized on donepezil 10 mg once daily and not currently on memantine: Initial: Memantine ER 7 mg/donepezil 10 mg once daily in the evening. Increase dose in increments of memantine ER 7 mg at intervals of ≥1 week to maintenance dose of memantine ER 14 mg/donepezil 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients stabilized on memantine (5 mg twice daily or 14 mg ER once daily) and donepezil 10 mg: May switch patients to memantine ER 14 mg/donepezil 10 mg once daily.</p></div>
<div class="block doha drugH1Div" id="F50988591"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F27657697"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F27235870"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F26715483"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to memantine, donepezil, piperidine derivatives, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F27657589"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Cholinesterase inhibitors may have vagotonic effects which may cause bradycardia and/or heart block with or without a history of cardiac disease; syncopal episodes have been associated with donepezil. Long-term use (eg, ≥1 year) may cause QT interval prolongation (Kho 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: May cause dose-related diarrhea, nausea, and/or vomiting; usually resolves in 1 to 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuroleptic malignant syndrome: Rare cases of neuroleptic malignant syndrome (NMS) have been reported (Matsumoto 2004; Warwick 2008). Discontinuation of donepezil therapy may be necessary in patients presenting with symptoms of NMS (eg, hyperthermia, irregular pulse or blood pressure, cardiac arrhythmia, diaphoresis, muscle rigidity, mental status changes, elevated creatine phosphokinase [CPK], unexplained high fever without additional symptoms).</p>
<p style="text-indent:-2em;margin-left:4em;">• Rhabdomyolysis: Rare cases of rhabdomyolysis (including acute renal failure) have been reported after a few months of therapy (Sahin 2014) or in the days following therapy initiation and dose increase (Aricept Canadian product monograph 2014). Use with caution in patients with risk factors for rhabdomyolysis (eg, concomitant medications associated with rhabdomyolysis, history of muscular disorders, uncontrolled hypothyroidism, renal/hepatic impairment). Discontinuation of therapy may be necessary for marked elevation of CPK levels and/or symptoms (eg, muscle pain, tenderness or weakness, malaise, fever, dark urine) suggesting rhabdomyolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac conduction abnormalities: Use with caution in patients with sick-sinus syndrome, bradycardia, or conduction abnormalities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic disease: Worsening of corneal condition has been observed in a clinical trial with memantine. Reversible corneal endothelial dysfunction may occur (Feng 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients at risk of ulcer disease (eg, previous history of ulcer disease or concomitant nonsteroidal anti-inflammatory drug use); cholinesterase inhibitors may increase gastric acid secretion. Monitor for symptoms of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with renal impairment; reduce dose in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with chronic obstructive pulmonary disease and/or asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder; cholinomimetics may potentially cause generalized seizures, although seizure activity may also result from Alzheimer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract obstruction: Use with caution in patients with bladder outlet obstruction or prostatic hyperplasia; cholinomimetics may cause or worsen outflow obstructions, including possible exacerbation of BPH symptoms (APA [Rabins 2007]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Urine pH: Clearance is significantly reduced by alkaline urine; use caution with medications, dietary changes, or patient conditions which may alter urine pH.</p></div>
<div class="block foc drugH1Div" id="F27773343"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule ER 24 Hour Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namzaric: Memantine hydrochloride 7 mg and donepezil hydrochloride 10 mg (7s) &amp; memantine hydrochloride 14 mg and donepezil hydrochloride 10 mg (7s) &amp; memantine hydrochloride 21 mg and donepezil hydrochloride 10 mg (7s) &amp; memantine hydrochloride 28 mg and donepezil hydrochloride 10 mg (7s) (28 ea) [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namzaric: Memantine hydrochloride 28 mg and donepezil hydrochloride 10 mg [contains corn starch, fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namzaric: Memantine hydrochloride 7 mg and donepezil hydrochloride 10 mg [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namzaric: Memantine hydrochloride 21 mg and donepezil hydrochloride 10 mg [contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namzaric: Memantine hydrochloride 14 mg and donepezil hydrochloride 10 mg [contains fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block geq drugH1Div" id="F27773341"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F28326119"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Namzaric Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7-10 mg (per each): $23.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7 &amp; 14 &amp; 21 &amp;28-10 MG (per each): $23.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">14-10 mg (per each): $23.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">21-10 mg (per each): $23.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">28-10 mg (per each): $23.62</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F27657701"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer in the evening without regard to meals. Swallow capsule whole; do not divide, chew, or crush. May open capsule and sprinkle entire contents on applesauce; swallow immediately. Do not divide contents of capsule into separate doses.</p></div>
<div class="block use drugH1Div" id="F26715482"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Alzheimer disease (moderate to severe):</b> Treatment of moderate to severe Alzheimer disease in patients stabilized on donepezil 10 mg once daily.</p></div>
<div class="block cyt drugH1Div" id="F26736574"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F26736571"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May increase the serum concentration of Memantine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Donepezil may enhance the neurotoxic (central) effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Memantine may diminish the therapeutic effect of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Memantine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Chlorprothixene. Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NMDA Receptor Antagonists: May enhance the adverse/toxic effect of Memantine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F27657587"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in some animal reproduction studies. See individual monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F27657588"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if donepezil or memantine are present in breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. See individual agents.</p></div>
<div class="block mop drugH1Div" id="F27657703"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cognitive function; symptoms of active or occult GI bleeding; symptoms of GI intolerance; weight.</p></div>
<div class="block pha drugH1Div" id="F27657692"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;margin-left:0em;">Memantine: Glutamate, the primary excitatory amino acid in the CNS, may contribute to the pathogenesis of Alzheimer disease (AD) by overstimulating various glutamate receptors leading to excitotoxicity and neuronal cell death. Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) type of glutamate receptors, located ubiquitously throughout the brain. Under normal physiologic conditions, the (unstimulated) NMDA receptor ion channel is blocked by magnesium ions, which are displaced after agonist-induced depolarization. Pathologic or excessive receptor activation, as postulated to occur during AD, prevents magnesium from reentering and blocking the channel pore resulting in a chronically open state and excessive calcium influx. Memantine binds to the intra-pore magnesium site, but with longer dwell time, and thus functions as an effective receptor blocker only under conditions of excessive stimulation; memantine does not affect normal neurotransmission.</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Donepezil: Alzheimer disease is characterized by cholinergic deficiency in the cortex and basal forebrain, which contributes to cognitive deficits. Donepezil reversibly and noncompetitively inhibits centrally-active acetylcholinesterase, the enzyme responsible for hydrolysis of acetylcholine. This appears to result in increased concentrations of acetylcholine available for synaptic transmission in the central nervous system.</p></div>
<div class="block phk drugH1Div" id="F27657694"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26732992"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alzetix | Lirpan plus</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Dementa d</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Eutebrol duo | Tonibral duo</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Eutebrol duo</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mixmazil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Eutebrol duo | Tonibral duo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Namzaric</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dezira combi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26248040">
<a name="26248040"></a>Feng MT, Price FW Jr, McKee Y, Price MO. Memantine-associated corneal endothelial dysfunction. <i>JAMA Ophthalmol.</i> 2015;133(10):1218-1220. doi:10.1001/jamaophthalmol.2015.2476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-and-memantine-drug-information/abstract-text/26248040/pubmed" id="26248040" target="_blank">26248040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22397651">
<a name="22397651"></a>Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. <i>N Engl J Med</i>. 2012;366(10):893-903. doi:10.1056/NEJMoa1106668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-and-memantine-drug-information/abstract-text/22397651/pubmed" id="22397651" target="_blank">22397651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32609550">
<a name="32609550"></a>Kho J, Ioannou A, Mandal AKJ, et al. Long term use of donepezil and QTc prolongation. <i>Clin Toxicol (Phila)</i>. 2021;59(3):208-214. doi:10.1080/15563650.2020.1788054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-and-memantine-drug-information/abstract-text/32609550/pubmed" id="32609550" target="_blank">32609550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14731314">
<a name="14731314"></a>Matsumoto T, Kawanishi C, Isojima D, et al. Neuroleptic malignant syndrome induced by donepezil. <i>Int J Neuropsychopharmacol</i>. 2004;7(1):101-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-and-memantine-drug-information/abstract-text/14731314/pubmed" id="14731314" target="_blank">14731314</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Namzaric (memantine and donepezil) [prescribing information]. Madison, NJ: Allergan USA, Inc; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18340692">
<a name="18340692"></a>Rabins PV, Blacker D, Rovner BW, et al; APA Work Group on Alzheimer's Disease and other Dementias. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. <i>Am J Psychiatry</i>. 2007;164(12 suppl):5-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-and-memantine-drug-information/abstract-text/18340692/pubmed" id="18340692" target="_blank">18340692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30771226">
<a name="30771226"></a>Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. <i>Med J Aust.</i> 2019;210(4):174-179. doi:10.5694/mja2.50015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-and-memantine-drug-information/abstract-text/30771226/pubmed" id="30771226" target="_blank">30771226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24864216">
<a name="24864216"></a>Sahin OZ, Ayaz T, Yuce S, et al. A rare case of acute renal failure secondary to rhabdomyolysis probably induced by donepezil [published online April 27, 2014]. <i>Case Rep Nephrol</i>. 2014;2014:214359. doi: 10.1155/2014/214359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-and-memantine-drug-information/abstract-text/24864216/pubmed" id="24864216" target="_blank">24864216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18212788">
<a name="18212788"></a>Warwick TC, Moningi V, Jami P, et al. Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine [published online January 22, 2008]. <i>Nat Clin Pract Neurol</i>. 2008;4(3):170-174. doi: 10.1038/ncpneuro0728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/donepezil-and-memantine-drug-information/abstract-text/18212788/pubmed" id="18212788" target="_blank">18212788</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 98777 Version 161.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
